Filed with ASX · · 2 pages · English
The company will provide additional equipment and support services for the trial, which is focused on cardiovascular health. This expansion reflects the growing demand for Conneqt's vascular assessment platforms from pharmaceutical sponsors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 9 November 2026 EXPANSION OF U.S. PHASE 2B CLINICAL TRIAL CONTRACT Highlights: ? Contract amendment executed to expand the Company’s U.S. Phase 2b clinical trial contract from 30 to 45 investigational sites. ? Incremental contract value of US$0.24 million (approximately A$0.34...
